Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 37 points (-0.2%) at 16,662 as of Friday, May 30, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,201 issues advancing vs. 1,742 declining with 169 unchanged. The Health Services industry currently sits down 0.4% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the industry include Intuitive Surgical ( ISRG), down 1.7%, Agilent Technologies ( A), down 1.1%, Catamaran ( CTRX), down 1.0%, Humana ( HUM), down 0.7% and Boston Scientific ( BSX), down 0.6%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Bruker ( BRKR) is one of the companies pushing the Health Services industry lower today. As of noon trading, Bruker is down $0.39 (-1.8%) to $20.96 on light volume. Thus far, 243,206 shares of Bruker exchanged hands as compared to its average daily volume of 778,500 shares. The stock has ranged in price between $20.82-$21.43 after having opened the day at $21.30 as compared to the previous trading day's close of $21.35. Bruker Corporation, together with its subsidiaries, designs, manufactures, sells, and services proprietary life science and materials research systems, and associated products worldwide. It operates through two segments, Scientific Instruments, and Energy & Supercon Technologies. Bruker has a market cap of $3.6 billion and is part of the health care sector. Shares are up 8.0% year-to-date as of the close of trading on Thursday. Currently there are 6 analysts that rate Bruker a buy, no analysts rate it a sell, and 4 rate it a hold. TheStreet Ratings rates Bruker as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Bruker Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.